Efficacy and tolerability of PTK787/ZK 222584 in a phase II study of post-transplant maintenance therapy in patients with multiple myeloma following high-dose chemotherapy and autologous stem cell transplant

Leuk Lymphoma. 2010 Aug;51(8):1577-9. doi: 10.3109/10428194.2010.488709.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Adult
  • Aged
  • Combined Modality Therapy
  • Female
  • Humans
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Multiple Myeloma / pathology
  • Multiple Myeloma / therapy*
  • Phthalazines / therapeutic use*
  • Prospective Studies
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyridines / therapeutic use*
  • Remission Induction
  • Stem Cell Transplantation*
  • Survival Rate
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • Phthalazines
  • Protein Kinase Inhibitors
  • Pyridines
  • vatalanib